AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Genzyme Waits to Hear Outcome of Patent Suit against Rival Drug Maker.

The Boston Globe (Boston, MA)

| November 30, 2001 | COPYRIGHT 2001 The Boston Globe. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

Byline: Naomi Aoki

Nov. 30--A judge's reading of a key phrase in a Genzyme Corp. patent appears to diminish the Cambridge company's chances of winning a patent fight against its cross-town neighbor, Transkaryotic Therapies Inc.

But the ruling in the pretrial motion didn't seem to dim Genzyme's hopes for victory. Saying the reading remained open to interpretation, the company announced plans to ask for a swift judgment against TKT.

"It's apparent that both sides see something in the ruling to support their position," said Genzyme spokesman Bo Piela. "Our position is that TKT's technology does infringe on this particular claim." "Based on the court's decision, we continue to believe that TKT does not infringe this patent," said TKT president and chief executive Richard Selden.

The two firms are developing nearly identical drugs to treat a rare genetic disorder, known as Fabry disease. They are racing to be the first, and perhaps sole, provider in the United States of a breakthrough therapy.

Both firms sought market exclusivity under the orphan drug act, aimed at encouraging drug development for rare diseases.

Some 2,000 to 4,000 people worldwide have Fabry. Such people lack an enzyme, alpha galactosidase, involved in breaking down fats. The buildup of fat causes pain, numbness, and cell damage, ultimately leaving patients at risk for kidney damage, heart disease, and stroke. ...

Related articles from newspapers, magazines, journals, and more
FDA Deals Blow to TKT Drug; Panel Says Clinical Data Don't Justify Approval.
Newspaper article from: Knight Ridder/Tribune Business News January 15, 2003 700+ words
By Naomi Aoki, The Boston Globe Knight Ridder/Tribune Business...agreed that the data presented by TKT on Replagal did not justify...diseases. Cambridge-based TKT and its crosstown rival, Genzyme...with SG Cowen in New York. "TKT has not. That definitely puts...
Two major investors challenge ShireOs $1.6M bid for TKT.(Shire Pharmaceuticals...
Newspaper article from: Pharma Marketletter July 11, 2005 700+ words
...shareholders, in a letter to TKT's board of directors dated...much higher price, we believe TKT should go back to managing its...according to a report in the Boston Globe. A second investment firm, Millenco, has said that TKT should at least have waited...
TKT Announces Agreement to be Acquired by Shire for $1.6 Billion.
Press release article from: PR Newswire April 21, 2005 700+ words
...SHQ) under which Shire has agreed to acquire TKT. Shire will pay $37 in cash for each share of TKT common stock, or approximately $1.6 billion...77, which is the last four week average of TKT's closing share price. Closing of this transaction...
TKT Forms European Company to Market Niche Protein Products -TKT Europe-5S AB...
Press release article from: PR Newswire July 17, 2000 700+ words
...Nasdaq: TKTX) today announced the formation of TKT Europe-5S AB to provide health care services, marketing, and distribution for TKT's Niche Protein(TM) products in Europe. TKT Europe-5S, headquartered in Sweden, will...
TKT FORMS EUROPEAN COMPANY TO MARKET NICHE PROTEIN PRODUCTS -TKT EUROPE-5S AB...
Press release article from: PR Newswire July 17, 2000 700+ words
...Nasdaq: TKTX) today announced the formation of TKT Europe-5S AB to provide health care services, marketing, and distribution for TKT's Niche Protein(TM) products in Europe. TKT Europe-5S, headquartered in Sweden, will...
TKT Announces Expiration of Both Hart-Scott-Rodino Waiting Period and SEC...
Press release article from: PR Newswire June 13, 2005 700+ words
...Pharmaceuticals Group plc. In addition, TKT also announced that the SEC's ten-day...previously announced on April 21, 2005, TKT and Shire signed a definitive agreement by which Shire has agreed to acquire TKT. Under the agreement, Shire has agreed...
TKT Confirms That Board of Directors Unanimously Recommends That Stockholders...
Press release article from: PR Newswire July 14, 2005 700+ words
...acquisition by Shire Pharmaceutical Group plc. at TKT's special meeting of stockholders on Wednesday...full, fair and immediate cash value to TKT stockholders. The board's objective throughout...value of our stockholders' investment in TKT. The board firmly and unanimously believes...
TKT to Hold Special Meeting of Stockholders on July 27, 2005.
Press release article from: PR Newswire June 27, 2005 700+ words
...previously announced on April 21, 2005, TKT and Shire signed a definitive agreement by which Shire has agreed to acquire TKT. Under the agreement, Shire has agreed to pay $37 in cash for each share of TKT common stock, or approximately $1.6...
For more facts and information, see all results
©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA